Mihael Hristos Polymeropoulos Purchases 10,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were bought at an average price of $4.46 per share, with a total value of $44,600.00. Following the transaction, the chief executive officer now directly owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. The trade was a 0.43 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Vanda Pharmaceuticals Stock Up 5.6 %

Shares of NASDAQ:VNDA opened at $4.71 on Thursday. The company has a market cap of $274.67 million, a P/E ratio of -14.72 and a beta of 0.74. The company’s fifty day moving average is $4.59 and its two-hundred day moving average is $4.80. Vanda Pharmaceuticals Inc. has a 12-month low of $3.71 and a 12-month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The firm had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million. Equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

VNDA has been the subject of several analyst reports. HC Wainwright upped their target price on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating for the company.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors have recently made changes to their positions in VNDA. SG Americas Securities LLC increased its stake in Vanda Pharmaceuticals by 88.5% in the 3rd quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 9,580 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,374 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Vanda Pharmaceuticals in the third quarter worth $143,000. Empowered Funds LLC increased its stake in shares of Vanda Pharmaceuticals by 5.3% in the third quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company’s stock worth $1,071,000 after acquiring an additional 11,524 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 7.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company’s stock worth $3,663,000 after acquiring an additional 55,567 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.